论文部分内容阅读
目的探讨胃癌患者P-糖蛋白、GST－π、Top－Ⅱ和p53的表达与胃癌发生发展的相关性。方法应用免疫组织化学（IHC）方法对66例胃癌组织和癌旁正常粘膜进行同位P－gp、GST－π、Top-Ⅱ和p53蛋白的检测。结果胃癌各蛋白的检测阳性率分别为P－gp36.36％（24／66），GST－π39．54％（26／66），Top－Ⅱ50％（33／66）和p5360．61（40／66）。Top－Ⅱ直在中等分化腺癌的阳性表达明显高于其它类型（P＜0．05）。p53的阳性表达与患者预后差有关（P＜0．01），并与P－gp的阳性表达密切相关（P＜0．01）。结论胃癌中P－gp低水平表达与胃癌的高度耐药不一致，可能存在其它的耐药机制，p53蛋白的累积与mdr耐药密切相关。
Objective To investigate the correlation between the expression of P-glycoprotein, GST-π, Top-II and p53 and the occurrence and development of gastric cancer. Methods Immunohistochemistry (IHC) was used to detect P-gp, GST-π, Top-II and p53 protein in 66 gastric cancer tissues and adjacent normal mucosa. RESULTS: The positive rate of each protein in gastric cancer was P-gp36.36% (24/66), GST-π39.54% (26/66), Top-II50% (33/66) and p5360.61 (40/ 66). The positive expression of Top-II in moderately differentiated adenocarcinoma was significantly higher than other types (P<0.05). The positive expression of p53 was associated with poor prognosis (P<0.01) and was closely related to the positive expression of P-gp (P<0.01). Conclusion The low level of P-gp in gastric cancer is inconsistent with the high resistance to gastric cancer. There may be other mechanisms of drug resistance. Accumulation of p53 protein is closely related to mdr resistance.